Citations (21)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Cynthia Willey, Marjolaine Gauthier-Loiselle, Martin Cloutier, Sherry Shi, Jessica Maitland, Robert Stellhorn & Myrlene Sanon Aigbogun. (2021) Regional variations in prevalence and severity of autosomal dominant polycystic kidney disease in the United States. Current Medical Research and Opinion 37:7, pages 1155-1162.
Read now
Read now
Manasi Datar, William Burchenal, Michael J. Donovan, Steven G. Coca, Elaine Wang & Thomas F. Goss. (2021) Payer budget impact of an artificial intelligence in vitro diagnostic to modify diabetic kidney disease progression. Journal of Medical Economics 24:1, pages 972-982.
Read now
Read now
Patrick Gagnon-Sanschagrin, Yawen Liang, Myrlene Sanon, Dorothee Oberdhan, Annie Guérin & Martin Cloutier. (2021) Excess healthcare costs in patients with autosomal dominant polycystic kidney disease by renal dysfunction stage. Journal of Medical Economics 24:1, pages 193-201.
Read now
Read now
Rashid A Barnawi, Rahaf Z Attar, Sultan S Alfaer & Osama Y Safdar. (2018) Is the light at the end of the tunnel nigh? A review of ADPKD focusing on the burden of disease and tolvaptan as a new treatment. International Journal of Nephrology and Renovascular Disease 11, pages 53-67.
Read now
Read now
Neeraj N Iyer, Nicholas J Vendetti, Daniel I Levy, Jack Mardekian, Marko A Mychaskiw & Joseph Thomas$suffix/text()$suffix/text(). (2018) Incremental health care resource utilization and expenditures associated with autosomal-dominant polycystic kidney disease. ClinicoEconomics and Outcomes Research 10, pages 693-703.
Read now
Read now
Luca Degli Esposti, Chiara Veronesi, Valentina Perrone, Stefano Buda & Antonio Santoro. (2017) Healthcare resource consumption and cost of care among patients with polycystic kidney disease in Italy. ClinicoEconomics and Outcomes Research 9, pages 233-239.
Read now
Read now
Articles from other publishers (15)
Juliana Smith, Orlando O. Harris, Deborah Adey & Meyeon Park. (2023) Barriers and facilitators to the transplant process among patients living with polycystic kidney disease: a qualitative Approach. BMC Nephrology 24:1.
Crossref
Crossref
Fouad T. Chebib & Ronald D. Perrone. (2023) Drug Development in Autosomal Dominant Polycystic Kidney Disease: Opportunities and Challenges. Advances in Kidney Disease and Health 30:3, pages 261-284.
Crossref
Crossref
Ronald D. Perrone, Dorothee Oberdhan, John Ouyang, Daniel G. Bichet, Klemens Budde, Arlene B. Chapman, Berenice Y. Gitomer, Shigeo Horie, Albert C.M. Ong, Vicente E. Torres, A. Neil Turner & Holly Krasa. (2023) OVERTURE: A Worldwide, Prospective, Observational Study of Disease Characteristics in Patients With ADPKD. Kidney International Reports 8:5, pages 989-1001.
Crossref
Crossref
Gregory Mader, Deirdre Mladsi, Myrlene Sanon, Molly Purser, Christine L. Barnett, Dorothee Oberdhan, Terry Watnick & Stephen Seliger. (2022) A disease progression model estimating the benefit of tolvaptan on time to end-stage renal disease for patients with rapidly progressing autosomal dominant polycystic kidney disease. BMC Nephrology 23:1.
Crossref
Crossref
Dorothee Oberdhan, Franz Schaefer, Jason C. Cole, Andrew C. Palsgrove, Ann Dandurand & Lisa Guay-Woodford. (2022) Polycystic Kidney Disease–Related Disease Burden in Adolescents With Autosomal Dominant Polycystic Kidney Disease: An International Qualitative Study. Kidney Medicine 4:3, pages 100415.
Crossref
Crossref
Vinusha Kalatharan, Eric McArthur, Danielle M Nash, Blayne Welk, Sisira Sarma, Amit X Garg & York Pei. (2021) Diagnostic accuracy of administrative codes for autosomal dominant polycystic kidney disease in clinic patients with cystic kidney disease. Clinical Kidney Journal 14:2, pages 612-616.
Crossref
Crossref
Vicente E. Torres, Arlene B. Chapman, Olivier Devuyst, Ron T. Gansevoort, Ronald D. Perrone, Jennifer Lee, Molly E. Hoke, Alvin Estilo & Olga Sergeyeva. (2021) Multicenter Study of Long-Term Safety of Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease. Clinical Journal of the American Society of Nephrology 16:1, pages 48-58.
Crossref
Crossref
Martin Cloutier, Ameur M. Manceur, Annie Guerin, Myrlene Sanon Aigbogun, Dorothee Oberdhan & Marjolaine Gauthier-Loiselle. (2020) The societal economic burden of autosomal dominant polycystic kidney disease in the United States. BMC Health Services Research 20:1.
Crossref
Crossref
Yeoungjee Cho, Gopala Rangan, Charlotte Logeman, Hyunjin Ryu, Benedicte Sautenet, Ronald D. Perrone, Annie-Claire Nadeau-Fredette, Reem A. Mustafa, Htay Htay, Michel Chonchol, Tess Harris, Talia Gutman, Jonathan C. Craig, Albert C.M. Ong, Arlene Chapman, Curie Ahn, Helen Coolican, Juliana Tze-Wah Kao, Ron T. Gansevoort, Vicente Torres, York Pei, David W. Johnson, Andrea K. Viecelli, Armando Teixeira-Pinto, Martin Howell, Angela Ju, Karine E. Manera & Allison Tong. (2020) Core Outcome Domains for Trials in Autosomal Dominant Polycystic Kidney Disease: An International Delphi Survey. American Journal of Kidney Diseases 76:3, pages 361-373.
Crossref
Crossref
Sarah Elshahat, Paul Cockwell, Alexander P. Maxwell, Matthew Griffin, Timothy O’Brien & Ciaran O’Neill. (2020) The impact of chronic kidney disease on developed countries from a health economics perspective: A systematic scoping review. PLOS ONE 15:3, pages e0230512.
Crossref
Crossref
Jacob A. Torres, Mina Rezaei, Caroline Broderick, Louis Lin, Xiaofang Wang, Bernd Hoppe, Benjamin D. CowleyJr.Jr., Vincenzo Savica, Vicente E. Torres, Saeed Khan, Ross P. Holmes, Michal Mrug & Thomas Weimbs. (2019) Crystal deposition triggers tubule dilation that accelerates cystogenesis in polycystic kidney disease. Journal of Clinical Investigation 129:10, pages 4506-4522.
Crossref
Crossref
Erin L. Murphy, Madeline L. Droher, Miriam S. DiMaio & Neera K. Dahl. (2018) Preimplantation Genetic Diagnosis Counseling in Autosomal Dominant Polycystic Kidney Disease. American Journal of Kidney Diseases 72:6, pages 866-872.
Crossref
Crossref
Daniel Eriksson, Linda Karlsson, Oskar Eklund, Hans Dieperink, Eero Honkanen, Jan Melin, Kristian Selvig & Johan Lundberg. (2017) Real-world costs of autosomal dominant polycystic kidney disease in the Nordics. BMC Health Services Research 17:1.
Crossref
Crossref
Matthew B. Lanktree & Arlene B. Chapman. (2017) New treatment paradigms for ADPKD: moving towards precision medicine. Nature Reviews Nephrology 13:12, pages 750-768.
Crossref
Crossref
Jessica Venugopal & Gustavo Blanco. (2017) On the Many Actions of Ouabain: Pro-Cystogenic Effects in Autosomal Dominant Polycystic Kidney Disease. Molecules 22:5, pages 729.
Crossref
Crossref